文献速递头颈外科小儿耳鼻咽喉

甲状腺肿瘤促结缔组织增生在散发性甲状腺髓样癌中优于术前血清降钙素作为手术生物标志物

Tumor desmoplasia outperforms preoperative serum calcitonin as surgical biomarker in sporadic medullary thyroid cancer.
PubMed 文献 · Head Neck · 2024-06-08

该分析纳入181例单侧散发性甲状腺髓样癌患者,术后按7级促结缔组织增生量表分级。当肿瘤促结缔组织增生达1%和≥50%时,淋巴结转移率从0%升至7%和83%,生化治愈率从100%降至95%和25%。结论认为肿瘤促结缔组织增生能极好区分淋巴结阴性及阳性散发性甲状腺髓样癌,而血清降钙素水平不能。

要点

  • 肿瘤促结缔组织增生达1%和≥50%时,淋巴结转移率分别为7%和83%,中位转移数分别为0和7.5。
  • 促结缔组织增生达1%和≥50%时,生化治愈率分别为95%和25%,而0%时为100%。
  • 甲状腺肿瘤直径和基础降钙素在七个促结缔组织增生组间广泛重叠,无法用于区分。

核心结论

  • 甲状腺肿瘤促结缔组织增生与血清降钙素水平不同,能极好区分淋巴结阴性和阳性的散发性甲状腺髓样癌,为精准手术开辟新途径。

研究设计与样本

  • 分析纳入181例单侧散发性甲状腺髓样癌患者,在甲状腺切除术和颈淋巴结清扫后按7级促结缔组织增生量表进行分级。

主要发现

  • 当甲状腺肿瘤促结缔组织增生达到1%和≥50%时,淋巴结转移率从0%分别增至7%(中位转移数0)和83%(中位转移数7.5)。
  • 当促结缔组织增生达到1%和≥50%时,显微镜下淋巴管侵犯率从0%分别增至3%和35%,甲状腺外侵犯率从0%分别增至5%和22%,结外生长率从0%分别增至0%和44%。
  • 当促结缔组织增生达到1%和≥50%时,生化治愈率从100%分别下降至95%和25%。
  • 甲状腺肿瘤直径和基础降钙素在七个促结缔组织增生组间广泛重叠,无法通过肿瘤大小或血清降钙素水平进行区分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Conceptually, thyroid tumor desmoplasia may be better suited for excluding node metastases in sporadic MTC than preoperative serum calcitonin levels. METHODS: This analysis included 181 patients with unilateral sporadic MTC graded on the 7-grade desmoplasia scale after thyroidectomy and neck dissection. RESULTS: When thyroid tumor desmoplasia reached 1% and ≥50%, node metastases increased from 0% to 7% (median of 0 metastases) and 83% (median of 7.5 metastases), microscopic lymphatic invasion from 0% to 3% and 35%, extrathyroid extension from 0% to 5% and 22%, and extranodal growth from 0% to 0% and 44%, whereas biochemical cure declined from 100% to 95% and 25%. Thyroid tumor diameters and basal calcitonin overlapped widely among the seven desmoplasia groups, precluding differentiation by thyroid tumor size or serum calcitonin levels. CONCLUSIONS: Thyroid tumor desmoplasia, unlike serum calcitonin levels, discriminates extremely well between node-negative and node-positive sporadic MTC, opening new avenues for precision surgery.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Machens A, Lorenz K, Bensch C, et al. Tumor desmoplasia outperforms preoperative serum calcitonin as surgical biomarker in sporadic medullary thyroid cancer. Head Neck. 2024. PMID: 38850101. doi:10.1002/hed.27827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。